ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Non-Invasive Test May Detect Lung Cancer In Early Stages

September 26, 2003

IVAX And It’s Portfolio

December 22, 1994

Specter Remains Chairman Of Labor-HHS Subcommittee.

February 2, 2001

NCI: The Times Have Been “Confusing,” Acting NCI Director Niederhuber Admits in Memo.

June 9, 2006

Are Cancer Drugs Getting Better? FDA’s Richard Pazdur Says “Yes”

February 14, 2014

President’s Budget Takes Care If R01s, P01s, Fattens Up NTP, Devastates Construction Grants

February 1, 1980